Roundup of the 7th European Breast Cancer Conference, Barcelona

Share :
Published: 15 Apr 2010
Views: 9493
Rating:
Save
Prof Gordon McVie - European Institute of Oncology, Milan

Although we can be optimistic thanks to the great advances that have been made in the field, there are still unacceptable levels of variation, with high cancer rates found in certain countries and socio-economic groups and a disparity in between the opinions of patients and doctors of what should be considered successful treatment.

Among the numerous studies on pregnancy and fertility, a number of key points arose, including: the low level of understanding among young women of how treatments can affect fertility; research indicating that treating pregnant women with chemotherapy poses a relatively low risk to the unborn child; a study showing that women who had been treated with chemotherapy did not have a reduced chance of becoming pregnant in the future.

The issue of communication has also come to light. A panel discussion identified a lack of clarity in the information provided outlining the risk of contracting cancer when a mutated BRC-1 or BRC-2 gene is identified.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
16 Sep 2024

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )
14 Sep 2024

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA
Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA
Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )
12 Jul 2024

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma

Dr Gregg Fields - Florida Atlantic University, Florida, USA
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )
12 Jul 2024

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )
26 Jun 2024

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA
Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )
26 Apr 2024

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )
25 Apr 2024

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)
Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )
25 Apr 2024